1. Milciclib
(Pipeline (en))
... PHA-848125 administered with prolonged schedules of administration (American Society of Clinical Oncology Annual Meeting2010,46th:June 7(Abs 3065)) Phase I study of the oral CDK-TRKA inhibitor PHA-848125 ...
On Friday,  January 27, at 1:30 PM, Gian Cesare Tron, from the Università degli Studi del Piemonte Orientale, A. Avogadro, Novara, Italy, will give an Oncology Seminar entitled "The search for novel ...
On Friday January 20th, at 1.30 PM, Dr. Andrea Necchi from the Department of Medicine, Medical Oncology 2 Unit, Fondazione IRCCS Istituto Nazionale dei Tumori in Milan will present an Oncology Seminar ...
4. Core services
(M.I.O. (en))
... to EVMPD via EV-Web Acknowledgment Management Clinical Data Management Data Management Plan Case Report Form, Design and Development (extensive library of Oncology specific modules available) ...
5. Partnerships
(M.I.O. (en))
Partnership with Lombardy Oncology Network (Rete Oncologica Lombarda) and Lombardy Hematology Network (Rete Ematologica Lombarda). Partnership with renowned European and US development sites: ...
6. Expertise
(M.I.O. (en))
... experience in oncology clinical development from cytotoxics to hormonals and targeted therapies: INDICATIONS Acute Leukemia Chronic Leukemia Multiple Myeloma Myelodisplastic Syndromes ...
Milano International Oncology operates as your partner in the clinical development and life-cycle management of compounds from first-time-in-man up to phase IV. MIO offers a full range of clinical developments ...
8. Capabilities
(Oncology (en))
Our expanding discovery and development capabilities array includes classical and innovative approaches to drug discovery, fully integrated within the Oncology division.  ...
9. Purinome Platform
(Technology Platforms (en))
The generation of novel chemotypes in support of our oncology research projects expanded in recent years from a canonical design of kinase targeted compound libraries to a broader interpretation of purinome ...
10. Kinase Platform
(Technology Platforms (en))
Our Oncology unit has developed a methodological platform to discover small molecule kinase inhibitors, which we refer to as the ‘Kinase Platform’. A panel of over 90 cloned and expressed kinases is ...
11. Danusertib
(Pipeline (en))
...  Phase I Pharmacokinetic and Pharmacodynamic Study of the Aurora Kinase Inhibitor Danusertib in Patients With Advanced or Metastatic Solid Tumors, Journal of Clinical Oncology 2009,27:30(5094-5101) A ...
12. Nemorubicin
(Pipeline (en))
... Oncology Annual Meeting 2009,May 31(Abs 4593) Sun Y,Yang J, Luo P, et al. Efficacy of Nemorubicin (MMDX) administered with iodinated oil via hepatic artery (IHA) to patients with unresectable primary ...
13. Publications
(Science Corner (en))
... R, Carpinelli P, Laffranchi B, de Jonge M. Journal Clinical Oncology (2009) 27(30), 5094-5101 Cell division cycle 7 kinase inhibitors: 1H-pyrrolo[2,3-b]pyridines, synthesis and structure-activity relationships ...
14. Oncology Seminars
(Science Corner (en))
We are glad to host external speakers to present their latest findings at our Oncology Seminars Series. Usual topics include themes related to the biology of cancer, chemical approaches, and in general ...
15. Meetings
(Science Corner (en))
... (Nerviano Medical Sciences) and Oncology network ofLombardy A. Isacchi, A. Galvani June 30 Joint Meeting on medicinal chemistry Catania, Italy Web link Oral presentation Cdc7 kinase inhibitors: a new ...
16. Collaborations and Licenses
(Oncology (en))
NMS Oncology is strategically committed to partnerships to promote discovery and development of innovative cancer treatments. Thus, we are open to establish R&D collaborative undertakings by applying ...
17. About NMS Oncology
(Oncology (en))
We fight cancer Our mission is to identify innovative agents for clinical development in areas of unmet medical needs in Oncology. From the “Discovery” phase onwards to clinical phase II, our aim is ...
18. History and Track record
(NMS Company (en))
... built by Farmitalia "Historical" track record The R&D Center in Nerviano has a longstanding and successful tradition of drug development, in particular in the oncology field. The history of the ...
19. Licensing and Alliances
(NMS Company (en))
... platforms, company aims to set up focused discovery alliances in the field of oncology with biotech and pharma companies and with academia , thus expanding the company's already established pipeline.  ...
20. Mission
(NMS Company (en))
... the biopharmaceutical industry and the scientific community, including the Regional Oncology Network (Rete Oncologica Lombarda). Our knowledge, experience, skills and technology, meet the highest standards ...
21. Who We Are
(NMS Company (en))
Nerviano Medical Sciences (NMS) is the largest pharmaceutical R&D facility in Italy and one of the largest oncology-focused, integrated discovery and development companies in Europe. Stemming from ...
Nerviano – 15 March, 2011 - Nerviano Medical Sciences (NMS), the largest pharmaceutical R&D facility in Italy and one of the leading oncology-focused, integrated discovery and development companies ...
Nerviano – 18 January, 2011 - Nerviano Medical Sciences (NMS), the largest pharmaceutical R&D facility in Italy and one of the leading oncology-focused, integrated discovery and development companies ...
Before the Italian Ambassador to Washington, Giulio Terzi di Sant'Agata, the current Chairman of Nerviano Medical Sciences, Alberto Sciumè, and John DeYoung, Vice President Oncology Business Development ...
Nerviano Italy, 8 October 2009 - Nerviano Medical Sciences today announced a publication in the peer-reviewed scientific journal, Journal of Clinical Oncology (*), of the first clinical trial performed ...
... the clinical experimentation of our Cdc7 inhibitor - explains Dr. Francesco Colotta, NMS Oncology VP - first of all represents an acknowledgment of the quality and innovation of Italian research in the ...
Nerviano, 21 October, 2008 - Nerviano Medical Sciences (NMS), the largest pharmaceutical R&D facility in Italy and one of the leading oncology-focused, integrated discovery and development companies ...
... in these days at the American Society of Clinical Oncology (ASCO) Conference, being held in Chicago from 30th May to 3rd June. For these three new compounds the scientists' attention will be called ...
... at Nerviano Medical Sciences Srl. (NMS), one of the leading oncology R&D companies in Europe. The article focuses on a new anti-cancer molecule that inhibits Cdc7, a target protein implicated in ...
... (NMS), the largest pharmaceutical R&D facility in Italy and one of the leading oncology-focused, integrated discovery and development companies in Europe, today announced an agreement with Genentech, ...
... facility in Italy and one of the largest oncology-focused, integrated discovery and development organizations in Europe. It was incorporated in May 2004 following a spin-off from Pfizer.Today NMS is a ...
... a privately held oncology company, in a stock for stock merger valued at $20 million. SMi stockholders could also receive a maximum of $15 million in additional consideration, payable in either cash or ...
... stage development of active compounds against new oncology targets provided by Bristol-Myers Squibb. Terms of the multi-year risk sharing collaboration include the potential for up to $150 million in clinical ...